Democratic lawmakers in Congress are pushing back on the health secretary’s decision to suspend public comment on much of HHS' business.
At Stanford conference, biotech leaders say Trump policies are disrupting science and FDA staffing, putting U.S. biomedical ecosystem at risk
The order could open the lucrative accreditation business to entrepreneurs that might launch new services more acceptable to the White House
Medetomidine emerges as a dangerous xylazine replacement in illicit fentanyl, complicating overdose response and posing severe withdrawal risks.
The agency's new, lengthy review of transgender health care sharply contradicts guidance from the American Medical Association.
Novo reached a coverage deal with CVS Caremark, giving its obesity drug Wegovy a boost as it competes against Lilly's Zepbound
NIH's withdrawal from the program, which helped slash infant deaths in the 2000s, comes as sleep-related deaths among infants have increased
In this week's edition of "Adam's Biotech Scorecard," Adam also explains why he's not worried — yet — about drugmakers reporting FDA delays.
